Skip to main content
. 2011 Jun 10;2(6):467–476. doi: 10.18632/oncotarget.293

Figure 1. Western blots of T308 catalytic phosphorylation site mutants.

Figure 1

The T308 phosphorylation site was mutated to alanine (T308A) or aspartate (T308D) in both myristylated and wild-type constructs. Akt phosphorylation and the downstream targets, GSK3β and S6 ribosomal protein are shown. Actin was used as a loading control, and HA is used to detect the overexpressed constructs. The T308A mutation blocks downstream signaling. The T308D mutation generates an incomplete mimic of phosphoserine and results in decreased signaling of myr-Akt-T308D.